Pfizer to Buy Remaining Shares of Trillium Therapeutics
Source: Dow Jones News By Dave Sebastian
Pfizer Inc. has agreed to buy shares it didn't already own in Trillium Therapeutics Inc., a company focused on developing therapies for cancer treatment, for an implied equity value of $2.26 billion.
The companies on Monday said Pfizer is paying $18.50 a share in cash. Trilium shares closed at $6.09 on Nasdaq on Friday.
The deal would boost Pfizer's oncology category with the addition of immuno-therapeutics for hematological malignancies, they said.
News 
Market Data 
Discover 
